Citigroup is set to report earnings before the bell

Citigroup is set to report earnings before the bell


Chief executive officer of Citigroup Jane Fraser visits FOX Business Network’s “Mornings With Maria” at Fox Business Network Studios on May 29, 2025 in New York City.

John Lamparski | Getty Images

Citigroup is scheduled to report fourth-quarter earnings before the opening bell Wednesday.

Here’s what Wall Street expects:

  • Earnings: $1.67 a share, according to LSEG
  • Revenue: $20.72 billion, according to LSEG
  • Net Interest Income: $14.85 billion, according to StreetAccount
  • Trading Revenue: Fixed income of $3.31 billion, equities of $1.19 billion, according to StreetAccount

Under CEO Jane Fraser, Citigroup is in the midst of a restructuring, selling off parts of its overseas operations, while also benefitting from U.S. banking deregulation.

Those are the reasons Wells Fargo banking analyst Mike Mayo calls Citigroup his top pick among bank stocks.

Analysts will be keen to hear whether Fraser sees momentum from last year carrying over into 2026.

On Tuesday, JPMorgan Chase posted results that exceeded expectations on better-than-expected trading revenue. Bank of America and Wells Fargo are also releasing Q4 results Wednesday, while Goldman Sachs and Morgan Stanley are scheduled for Thursday.

This story is developing. Please check back for updates.



Source

Nike cuts 1,400 roles in second round of layoffs this year
Business

Nike cuts 1,400 roles in second round of layoffs this year

People walk past a Nike store in New York City, on April 2, 2025. Kylie Cooper | Reuters Nike announced a new round of layoffs on Thursday impacting approximately 1,400 roles across the organization, mostly concentrated in its technology department. In a note from COO Venkatesh Alagirisamy, the company said the layoffs were part of […]

Read More
Trump administration moves to reclassify cannabis in major shift that could expand research
Business

Trump administration moves to reclassify cannabis in major shift that could expand research

The Trump administration moved Thursday to reclassify cannabis under federal law, which could significantly expand scientific research into the drug’s medical uses. The change would not legalize the drug at the federal level, but shift cannabis from its current status as a Schedule I substance to Schedule III under the U.S. Drug Enforcement Administration’s controlled […]

Read More
Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free
Business

Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free

U.S. President Donald Trump (C) speaks during an event on advancing health care affordability in the Oval Office of the White House on April 23, 2026 in Washington, DC. Alex Wong | Getty Images Regeneron agreed to lower U.S. drug prices for some Americans as part of a deal with President Donald Trump, the White […]

Read More